Cell Medica, which develops, manufactures and markets cellular immunotherapies for the treatment of cancer and infections, has announced two key appointments for its senior management team.
Alain Prolong (pictured) has been appointed Senior Vice President, Head of Manufacturing Operations, and Stefanos Theoharis has been appointed Senior Vice President and Head of Pipeline Strategy and Corporate Partnering.
Alain will develop and execute the Company’s strategy for commercial supply of patient-specific cell products on a global level. Through his previous positions at GSK Vaccines, Crucell, Merck Serono and Roche, Alain has extensive experience in product development and scaling pharmaceutical manufacturing operations. Alain will also oversee Cell Medica’s contract manufacturing relationships.
Stefanos will spearhead the company’s pipeline development strategy and strategic partnerships. Stefanos’s understanding of development opportunities in cell and gene therapies will accelerate Cell Medica’s pipeline strategy, which includes sourcing new products through academic and corporate collaborations as well as from in-house R&D.
